GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

▤ Summary

GeneDx Holdings faces a securities class action tied to alleged misrepresentations about its acquisition performance and business outlook. The complaint centers on disclosures made after the company reported weaker margins, missed revenue estimates, and lowered full-year guidance. The filing also cites a $31.2 million impairment loss linked to the earlier Fabric Genomics acquisition. Investors who bought shares during the class period have until August 3, 2026 to seek lead plaintiff status.

▦ Linked Companies